These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 16258518)
1. Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Korja M; Finne J; Salmi TT; Kalimo H; Karikoski R; Tanner M; Isola J; Haapasalo H Mod Pathol; 2005 Dec; 18(12):1599-605. PubMed ID: 16258518 [TBL] [Abstract][Full Text] [Related]
2. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method. Bhargava R; Oppenheimer O; Gerald W; Jhanwar SC; Chen B Diagn Mol Pathol; 2005 Jun; 14(2):72-6. PubMed ID: 15905689 [TBL] [Abstract][Full Text] [Related]
3. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898 [TBL] [Abstract][Full Text] [Related]
4. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319 [TBL] [Abstract][Full Text] [Related]
5. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167 [TBL] [Abstract][Full Text] [Related]
6. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
7. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185 [TBL] [Abstract][Full Text] [Related]
8. Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach. H'Mida Ben Brahim D; Trabelsi S; Chabchoub I; Gargouri I; Harrabi I; Moussa A; Chourabi M; Haddaji M; Sassi S; Mougou S; Gribaa M; Ben Ahmed S; Zakhama A; Nouri A; Saad A Tunis Med; 2015; 93(8-9):527-31. PubMed ID: 26815518 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma. Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373 [TBL] [Abstract][Full Text] [Related]
10. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746 [TBL] [Abstract][Full Text] [Related]
11. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782 [TBL] [Abstract][Full Text] [Related]
12. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients. Wang M; Zhou C; Cai R; Li Y; Gong L Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395 [TBL] [Abstract][Full Text] [Related]
13. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155 [TBL] [Abstract][Full Text] [Related]
14. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909 [TBL] [Abstract][Full Text] [Related]
15. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology. Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077 [TBL] [Abstract][Full Text] [Related]
16. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190 [TBL] [Abstract][Full Text] [Related]
17. Concomitant DDX1 and MYCN gain in neuroblastoma. Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020 [TBL] [Abstract][Full Text] [Related]
18. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439 [TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000 [TBL] [Abstract][Full Text] [Related]
20. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]